CRHT2

2 trials

Sponsors

Novartis

Conditions

asthma N/A

Phase 3

A 52-week, multicenter, randomized, double-blind, placebocontrolled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe asthma

RecruitingNL-OMON53380

Novartisasthma N/A

Start: 2016-03-11Target: 15Updated: 2024-02-28

A 2-treatment period, randomized, placebo-controlled, multicenter parallel-group study to assess the safety of QAW039 when added to existing asthma therapy in GINA steps 3, 4 and 5 patients with uncontrolled asthma

Active, not recruitingNL-OMON48545

Novartisasthma N/A

Start: 2017-11-07Target: 15Updated: 2024-02-28